ArticleOncology letters2022

Aumolertinib challenge as an optional treatment in advanced non small-cell lung cancer after osimertinib failure with epidermal growth factor receptor-sensitive mutation: A case series.

Xinjing Ding et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.